| Literature DB >> 19755776 |
Arito Yamane1, Norifumi Tsukamoto, Takayuki Saitoh, Hideki Uchiumi, Hiroshi Handa, Masamitsu Karasawa, Yoshihisa Nojima, Hirokazu Murakami.
Abstract
Although all-trans retinoic acid (ATRA) is widely used in acute promyelocytic leukemia (APL), there is little data as to whether or not ATRA is useful for patients with liver and renal failure. A 63-year-old APL patient, complicated by Child-Pugh class A liver cirrhosis and chronic renal failure (creatinine 3.2 mg/dL), was successfully treated with 45 mg/m(2)/day of ATRA. With three courses of chemotherapy, complete remission has been maintained for four years in this patient. Serum trough and maximum ATRA concentration, and the area under the curve (AUC) were not elevated. These observations suggest that full-dose ATRA therapy might be safely applicable to such a complicated case with APL.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19755776 DOI: 10.2169/internalmedicine.48.2358
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271